IMUNON’s CEO Presents Business Overview to Investors and Senior Biopharmaceutical Professionals at the BIO 2023 International Convention
2023年6月8日 - 9:30PM
IMUNON, Inc. (NASDAQ: IMNN), a
clinical-stage drug-development company focused on developing
non-viral DNA-mediated immunotherapy and next-generation vaccines,
announces that President and Chief Executive Officer Dr. Corinne Le
Goff presented an overview of IMUNON’s business progress and its
progress to an audience of investors and biopharmaceutical
professionals at the BIO 2023 International Convention underway in
Boston.
Dr. Le Goff’s presentation highlighted the
strength of the IMUNON leadership team and the status of the
Company’s TheraPlas nucleic acid therapeutics platform and its
PlaCCine nucleic acid vaccine platform. She provided context for
the use of DNA in these platforms, updates on the pipeline and
clinical trials including the combination trial with Avastin, and
an overview of IMUNON’s financial status. Dr. Le Goff’s
presentation is available here.
Importantly, Dr. Le Goff emphasized that IMUNON
is making substantial progress in its mission to develop new
medicines that harness the building blocks of life to work in
harmony with the body’s immune system. For the PlaCCine and
TheraPlas platform technologies, Dr. Le Goff described mechanisms
of action and provided a closer look at the promising clinical
results generated to-date. She also provided background on the use
of DNA in these medicines, characterizing its performance in terms
of durability, development speed, and ease of manufacturing,
shipping and storing.
Separately, Dr. Le Goff reminded attendees of
IMUNON’s strong cash position, stating, “IMUNON is fortunate to
have the cash runway we need to complete all the programs we
currently have underway.”
Members of the IMUNON management team took
advantage of the BIO 2023 International Convention to hold meetings
with existing and prospective investors and R&D partners. BIO
describes the conference as "the world's leading gathering of
biotechnology and life science leaders." The BIO 2023 convention
brought together more than 18,000 delegates from over 60 countries
to network, learn and collaborate on the latest trends and
innovations in the industry. Attendees included representatives of
biotechnology and pharmaceutical companies, research institutes and
universities, government agencies, venture capital firms,
non-profit organizations, patient advocacy groups, investment
analysts and journalists.
About IMUNON
IMUNON is a fully integrated, clinical stage
biotechnology company focused on advancing a portfolio of
innovative treatments that harness the body’s natural mechanisms to
generate safe, effective and durable responses across a broad array
of human diseases, constituting a differentiating approach from
conventional therapies.
IMUNON has two platform technologies: the
TheraPlas modality for the development of immunotherapies and other
anti-cancer nucleic acid-based therapies, and the PlaCCine modality
for the development of nucleic acid vaccines for infectious
diseases and cancer. The Company’s lead clinical program, IMNN-001,
is a DNA-based immunotherapy for the localized treatment of
advanced ovarian cancer currently in Phase 2 development. IMNN-001
works by instructing the body to produce safe and durable levels of
powerful cancer-fighting molecules, such as interleukin-12 and
interferon gamma, at the tumor site. Additionally, the Company is
conducting preclinical proof-of-concept studies on a nucleic acid
vaccine candidate targeting the SARS-CoV-2 virus to validate its
PlaCCine platform. IMUNON’s platform technologies are based on the
delivery of nucleic acids with novel synthetic delivery systems
that are independent of viral vectors or devices. IMUNON will
continue to leverage these platforms and to advance the
technological frontier of nucleic acid-based products to better
serve patients with difficult-to-treat conditions. For more
information on IMUNON, visit www.imunon.com.
Forward-Looking Statements
IMUNON wishes to inform readers that
forward-looking statements in this news release are made pursuant
to the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995. Readers are cautioned that such
forward-looking statements involve risks and uncertainties
including, without limitation, unforeseen changes in the course of
research and development activities and in clinical trials; the
uncertainties of and difficulties in analyzing interim clinical
data; the significant expense, time and risk of failure of
conducting clinical trials; the need for IMUNON to evaluate its
future development plans; possible acquisitions or licenses of
other technologies, assets or businesses; possible actions by
customers, suppliers, competitors or regulatory authorities; and
other risks detailed from time to time in IMUNON’s periodic reports
and prospectuses filed with the Securities and Exchange Commission.
IMUNON assumes no obligation to update or supplement
forward-looking statements that become untrue because of subsequent
events, new information or otherwise.
Contacts: |
|
IMUNON |
LHA Investor Relations |
Jeffrey
W. Church |
Kim
Sutton Golodetz |
Executive
Vice President, CFO |
212-838-3777 |
and
Corporate Secretary |
Kgolodetz@lhai.com |
609-482-2455 |
|
jchurch@imunon.com |
|
# # #
Imunon (NASDAQ:IMNN)
過去 株価チャート
から 4 2024 まで 5 2024
Imunon (NASDAQ:IMNN)
過去 株価チャート
から 5 2023 まで 5 2024